Ann-Marie Tantoco, Sherif M Badawy, Cheryl K Lee, Jeffrey Merz, Maura Steed, Mark Kluk, Ajay Bhasin
{"title":"镰状细胞病儿童阿片类药物滥用诊断代码的患病率","authors":"Ann-Marie Tantoco, Sherif M Badawy, Cheryl K Lee, Jeffrey Merz, Maura Steed, Mark Kluk, Ajay Bhasin","doi":"10.1080/08880018.2024.2437045","DOIUrl":null,"url":null,"abstract":"<p><p>Hospitalized patients with sickle cell disease (SCD) may use opioid medications for both acute and chronic pain management. Use of these medications may unintentionally generate diagnostic codes for opioid misuse including \"opioid use,\" \"opioid abuse,\" and \"opioid dependence,\" which connote a behavioral problem or addiction. In this study, we sought to compare diagnostic codes for opioid misuse amongst hospitalized patients with and without SCD. We performed a cross-sectional study of hospitalized non-obstetric, non-surgical, and non-elective patients with SCD using the National Inpatient Sample published by the Agency for Healthcare Research and Quality Hospital Cost Utilization Project during years 2016-2019. We used descriptive statistics to characterize patient demographics and opioid misuse diagnostic codes. We used Chi Square testing to compare rates of diagnostic codes for opioid misuse between patients with and without SCD. There were 165 ± 3 hospitalizations for SCD per 100,000 US population. Patients with SCD had higher rates of opioid misuse diagnostic codes for \"opioid use\" (0.3% vs 0.1%, <i>p</i> < 0.001) and \"opioid dependence\" (4.5% vs 1.6%, <i>p</i> < 0.001), but a lower rate for \"opioid abuse\" (0.2% vs 0.3%, <i>p</i> < 0.001). We found that diagnostic codes for opioid misuse are higher in those with SCD than without SCD, even at young ages, which impart substantial bias toward these patients.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-10"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prevalence of opioid misuse diagnostic codes in children with sickle cell disease.\",\"authors\":\"Ann-Marie Tantoco, Sherif M Badawy, Cheryl K Lee, Jeffrey Merz, Maura Steed, Mark Kluk, Ajay Bhasin\",\"doi\":\"10.1080/08880018.2024.2437045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hospitalized patients with sickle cell disease (SCD) may use opioid medications for both acute and chronic pain management. Use of these medications may unintentionally generate diagnostic codes for opioid misuse including \\\"opioid use,\\\" \\\"opioid abuse,\\\" and \\\"opioid dependence,\\\" which connote a behavioral problem or addiction. In this study, we sought to compare diagnostic codes for opioid misuse amongst hospitalized patients with and without SCD. We performed a cross-sectional study of hospitalized non-obstetric, non-surgical, and non-elective patients with SCD using the National Inpatient Sample published by the Agency for Healthcare Research and Quality Hospital Cost Utilization Project during years 2016-2019. We used descriptive statistics to characterize patient demographics and opioid misuse diagnostic codes. We used Chi Square testing to compare rates of diagnostic codes for opioid misuse between patients with and without SCD. There were 165 ± 3 hospitalizations for SCD per 100,000 US population. Patients with SCD had higher rates of opioid misuse diagnostic codes for \\\"opioid use\\\" (0.3% vs 0.1%, <i>p</i> < 0.001) and \\\"opioid dependence\\\" (4.5% vs 1.6%, <i>p</i> < 0.001), but a lower rate for \\\"opioid abuse\\\" (0.2% vs 0.3%, <i>p</i> < 0.001). We found that diagnostic codes for opioid misuse are higher in those with SCD than without SCD, even at young ages, which impart substantial bias toward these patients.</p>\",\"PeriodicalId\":19746,\"journal\":{\"name\":\"Pediatric Hematology and Oncology\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08880018.2024.2437045\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2024.2437045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
住院的镰状细胞病(SCD)患者可以使用阿片类药物治疗急性和慢性疼痛。使用这些药物可能会无意中产生阿片类药物滥用的诊断代码,包括“阿片类药物使用”、“阿片类药物滥用”和“阿片类药物依赖”,这意味着行为问题或成瘾。在这项研究中,我们试图比较住院患者中有和没有SCD的阿片类药物滥用的诊断代码。我们对住院的非产科、非手术和非选择性SCD患者进行了横断面研究,使用了2016-2019年医疗保健研究和质量医院成本利用项目机构发布的全国住院患者样本。我们使用描述性统计来描述患者人口统计学特征和阿片类药物滥用诊断代码。我们使用卡方检验来比较有和无SCD患者阿片类药物滥用诊断代码的比率。每10万人中有165±3人因SCD住院。SCD患者在“阿片类药物使用”诊断代码中有更高的阿片类药物滥用率(0.3% vs 0.1%, p p p
The prevalence of opioid misuse diagnostic codes in children with sickle cell disease.
Hospitalized patients with sickle cell disease (SCD) may use opioid medications for both acute and chronic pain management. Use of these medications may unintentionally generate diagnostic codes for opioid misuse including "opioid use," "opioid abuse," and "opioid dependence," which connote a behavioral problem or addiction. In this study, we sought to compare diagnostic codes for opioid misuse amongst hospitalized patients with and without SCD. We performed a cross-sectional study of hospitalized non-obstetric, non-surgical, and non-elective patients with SCD using the National Inpatient Sample published by the Agency for Healthcare Research and Quality Hospital Cost Utilization Project during years 2016-2019. We used descriptive statistics to characterize patient demographics and opioid misuse diagnostic codes. We used Chi Square testing to compare rates of diagnostic codes for opioid misuse between patients with and without SCD. There were 165 ± 3 hospitalizations for SCD per 100,000 US population. Patients with SCD had higher rates of opioid misuse diagnostic codes for "opioid use" (0.3% vs 0.1%, p < 0.001) and "opioid dependence" (4.5% vs 1.6%, p < 0.001), but a lower rate for "opioid abuse" (0.2% vs 0.3%, p < 0.001). We found that diagnostic codes for opioid misuse are higher in those with SCD than without SCD, even at young ages, which impart substantial bias toward these patients.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.